Aemetis, Inc (NASDAQ:AMTX)‘s stock had its “neutral” rating restated by analysts at FBR & Co in a research report issued on Saturday. They presently have a $2.00 price objective on the specialty chemicals company’s stock. FBR & Co’s price objective would suggest a potential upside of 85.19% from the company’s previous close.

Separately, Zacks Investment Research raised shares of Aemetis from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th.

Shares of Aemetis (NASDAQ AMTX) opened at 1.08 on Friday. Aemetis has a 52-week low of $0.95 and a 52-week high of $2.50. The stock’s market cap is $21.41 million. The firm’s 50-day moving average price is $1.21 and its 200-day moving average price is $1.28.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at

An institutional investor recently raised its position in Aemetis stock. Geneva Advisors LLC boosted its stake in Aemetis, Inc (NASDAQ:AMTX) by 3.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,562,431 shares of the specialty chemicals company’s stock after buying an additional 50,800 shares during the period. Geneva Advisors LLC owned 7.93% of Aemetis worth $2,078,000 as of its most recent SEC filing. 18.87% of the stock is currently owned by hedge funds and other institutional investors.

Aemetis Company Profile

Aemetis, Inc is an international renewable fuels and biochemicals company. The Company is focused on the production of fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products by conversion of first-generation ethanol and biodiesel plants into biorefineries.

Receive News & Ratings for Aemetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis Inc and related companies with's FREE daily email newsletter.